Healthcare / BiotechnologySwiss
$12.44
-0.64 (-4.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-10.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$259M
P/E
N/A
•EV/EBITDA
N/A
•ROE
118.9%
↑Gross Margin
N/A
•Debt/Equity
-3.43
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+46.4%
FCF CAGR
—
FCF margin
168.9%
FCF / Net income
-2.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.1M · net income $-13.2M · FCF $32.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.1M | $19.1M | $51.4M | $9.1M | $6.1M |
| Net Income | $-13.2M | $-13.2M | $15.8M | $-16.2M | $-17.5M |
| EBITDA | $-7.8M | $-7.8M | $25.9M | $-11.8M | $-13.3M |
| EPS | — | — | 0.77 | -0.91 | -0.98 |
| Operating Margin | -24.6% | -24.6% | 50.9% | -128.4% | -218.3% |
| Net Margin | -69.2% | -69.2% | 30.8% | -179.1% | -287.1% |
| Balance Sheet | |||||
| Debt/Equity | -3.43 | -3.43 | 34.62 | -1.62 | -3.25 |
| Current Ratio | 0.76 | 0.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $32.3M | $32.3M | $-17.6M | $-10.2M | $-11.1M |
| Returns | |||||
| ROE | 118.9% | 118.9% | 1086.6% | 54.2% | 124.7% |
| Valuation | |||||
| P/E | — | — | 11.44 | — | — |
| EV/EBITDA | — | — | 8.67 | — | — |
| P/B | — | — | 124.33 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -62.8% | -62.8% | 467.4% | 48.6% | — |
| EPS Growth | — | — | 184.6% | 7.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+64.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.77 → n/d
Residual
+64.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.